DPHARMA
Quarterly rpt on consolidated results for the financial period ended 30 Jun 2018
Amended Announcements
Please refer to the earlier announcement reference number: FRA-24082018-00066
CCM DUOPHARMA BIOTECH BERHAD |
Financial Year End | 31 Dec 2018 |
Quarter | 2 Qtr |
Quarterly report for the financial period ended | 30 Jun 2018 |
The figures | have not been audited |
Remarks : |
Amendments have been made to columns 1 to 4 of item no. 5, columns 2 and 4 of item no. 6 and columns 1 and 2 of item no. 7 of Part A2: Summary of Key Financial Information in respect of the Basic earnings/(loss) per share (Subunit), Proposed/ Declared Dividend per share and Net Assets per share attributable to ordinary equity holders of the parent. An amendment has also been made in respect of Note B11(a) and (b) in relation to the Basic EPS and the Dilutive EPS respectively, on pages 4 and 5 of the Notes to Interim Financial Report for the Quarterly Report on Results for the Financial Year Ended 30 June 2018, as attached. As announced by the Company on 20 June 2018, the bonus issue by the Company had been completed following the listing of and quotation for 371,943,071 new bonus shares on the Main Market of Bursa Malaysia Securities Berhad on 20 June 2018. The calculations of the Basic EPS (sen), Dilutive EPS (sen), Proposed/ Declared dividend per share and Net Assets per share attributable to ordinary equity holders of the parent have been amended to take into account of the effect of the bonus issue. |
- Default Currency
- Other Currency
Currency: Malaysian Ringgit (MYR)
SUMMARY OF KEY FINANCIAL INFORMATION
|
INDIVIDUAL PERIOD
|
CUMULATIVE PERIOD
|
||||
CURRENT YEAR QUARTER
|
PRECEDING YEAR CORRESPONDING QUARTER |
CURRENT YEAR TO DATE
|
PRECEDING YEAR CORRESPONDING PERIOD |
||
30 Jun 2018
|
30 Jun 2017
|
30 Jun 2018
|
30 Jun 2017
|
||
$$'000
|
$$'000
|
$$'000
|
$$'000
|
||
1 | Revenue |
123,991
|
117,049
|
257,250
|
240,355
|
2 | Profit/(loss) before tax |
12,915
|
12,642
|
26,170
|
24,764
|
3 | Profit/(loss) for the period |
10,339
|
9,641
|
20,986
|
19,205
|
4 | Profit/(loss) attributable to ordinary equity holders of the parent |
10,339
|
9,653
|
20,986
|
19,217
|
5 | Basic earnings/(loss) per share (Subunit) |
1.59
|
1.48
|
3.22
|
2.95
|
6 | Proposed/Declared dividend per share (Subunit) |
1.50
|
1.07
|
1.50
|
1.07
|
AS AT END OF CURRENT QUARTER
|
AS AT PRECEDING FINANCIAL YEAR END
|
||||
7 |
Net assets per share attributable to ordinary equity holders of the parent ($$) |
0.7500
|
0.7400
|
Definition of Subunit:
In a currency system, there is usually a main unit (base) and
subunit that is a fraction amount of the main unit.
Example for the subunit as follows:
Country | Base Unit | Subunit |
Malaysia | Ringgit | Sen |
United States | Dollar | Cent |
United Kingdom | Pound | Pence |
Announcement Info
Company Name | CCM DUOPHARMA BIOTECH BERHAD |
Stock Name | CCMDBIO |
Date Announced | 26 Nov 2018 |
Category | Financial Results |
Reference Number | FRA-26112018-00024 |